Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing
and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.
January 4, 1989
Jeffrey LeidenChairman of the Board, President, Chief Executive Officer
Ian SmithChief Financial Officer, Chief Operating Officer, Executive Vice President
Michael PariniExecutive Vice President, Chief Legal and Administrative Officer
David AltshulerExecutive Vice President - Global Research, Chief Scientific Officer
Stuart ArbuckleExecutive Vice President, Chief Commercial Officer
Jeffrey ChodakewitzExecutive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer
Amit SachdevExecutive Vice President, Chief Regulatory Officer and Chief of Staff to the CEO
Paul SilvaSenior Vice President, Corporate Controller
Bruce SachsLead Director, Independent Director
Elaine UllianCo-Lead Independent Director
Sangeeta BhatiaIndependent Director
50 Northern Ave Boston, MA United States Phone: +1 617 341-6393 www.vrtx.com
Net income grew year over year last quarter from a loss of (U.S.)$0.17 per share to a gain of (U.S.) $1.00.